9月5日，中国证监会发布《关于同意苏州丰倍生物科技股份有限公司首次公开发行股票注册的批复》。据悉，丰倍生物拟在上交所上市，国泰海通证券为其 保荐机构，拟募资10亿元。 | 索 引 号 | bm56000001/2025-00010520 | র্ণ 参 | | --- | --- | --- | | 发布机构 | | 发文目期 | | SP 标 | 关于同意苏州丰倍生物科技股份有限公司首次公开发行股票注册的批复 | | | 文 름 | 证监许可〔2025〕1958号 | 主题词 | 招股书显示，丰倍生物是一家废弃资源综合利用领域的高新技术企业，主要以废弃油脂生产资源化产品。基于长期的研发投入和产业实践，公司在废弃油脂 资源综合利用的深度及广度上不断拓展，形成了"废弃油脂—生物燃料(生物柴油)—生物基材料"的废弃资源再生产业链。 截至2024年末，公司现有生物柴油产能10.5万吨，产能规模位居我国生物柴油行业第六。结合主要资源化产品生物柴油的产量来看，根据USDA统计，2024 年我国生物柴油产量约为171万吨，发行人生物柴油产量为8.01万吨，对应以产量计的公司生物柴油市场占有率约为4.68%。 ...

Core Viewpoint - Fengbei Biotechnology Co., Ltd. has successfully submitted its IPO registration on the Shanghai Stock Exchange, focusing on the comprehensive utilization of waste resources, particularly converting waste oils into biodiesel and bio-based materials, but faces challenges including performance decline due to EU anti-dumping policies and weak R&D investment [1][10][24]. Group 1: Company Overview - Fengbei Biotechnology is a high-tech enterprise in the waste resource utilization sector, primarily producing biodiesel and bio-based materials from waste oils, forming a recycling industry chain [2][5]. - The company was established in July 2014 and transitioned to a joint-stock company in January 2022, with its founder, Ping Yuan, holding 85.40% of the shares [4][5]. Group 2: Financial Performance - For the years 2022 to 2024, Fengbei's operating revenues were 1.709 billion, 1.728 billion, and 1.948 billion yuan, with year-on-year growth rates of 31.89%, 1.12%, and 12.75% respectively [10][11]. - The net profit attributable to the parent company for the same period was 133 million, 130 million, and 124 million yuan, showing a decline of 2.73% and 4.54% in the last two years [10][11]. Group 3: Market Challenges - The company has faced significant challenges due to the EU's anti-dumping investigations, which have led to a sharp decline in sales in the EU market, affecting overall profitability [15][18]. - Sales to the EU dropped from 3.30 billion yuan in 2021 to 505 million yuan in the first half of 2024, indicating a substantial market shift [15][18]. Group 4: R&D and Competitive Position - Fengbei's R&D expenses as a percentage of operating income were 3.00%, 3.39%, and 2.75% from 2022 to 2024, which is below the industry average [21][22]. - The company claims its competitive advantage lies in basic research, material development, and application development, but it risks falling behind competitors if R&D investment does not increase [24]. Group 5: Financial Health - As of the end of 2024, Fengbei's cash reserves were 167 million yuan, while short-term borrowings amounted to 173 million yuan, indicating potential liquidity issues [24].

Core Viewpoint - Fengbei Bio is a high-tech enterprise in the field of waste resource utilization, focusing on converting waste oils into biodiesel and bio-based materials, but faces challenges such as declining performance due to EU anti-dumping policies and insufficient R&D investment [2][14][20]. Company Overview - Fengbei Bio was established in July 2014 and transitioned to a joint-stock company in January 2022, with a registered capital of 5 million yuan [4]. - The founder, Ping Yuan, holds 85.40% of the shares, maintaining absolute control over the company [4][5]. - The company has acquired stakes in several related companies to enhance its operational scale and market competitiveness [4][6]. Financial Performance - Revenue for 2022, 2023, and projected 2024 is 1.709 billion yuan, 1.728 billion yuan, and 1.948 billion yuan, respectively, showing a growth of 31.89%, 1.12%, and 12.75% [9][10]. - Net profit for the same years is 133.34 million yuan, 129.71 million yuan, and 123.82 million yuan, indicating a decline of 2.73% and 4.54% in 2023 and 2024 [9][10]. - The company has distributed significant cash dividends of 15 million yuan and 16.14 million yuan in 2022 and 2023, respectively, totaling 31.14 million yuan [7]. Market Challenges - The company faces a significant decline in sales to the EU due to anti-dumping investigations, with sales figures dropping from 3.30 billion yuan in 2021 to 505.12 million yuan in the first half of 2024 [16][18]. - The EU accounts for 34.65% of global biodiesel consumption, making it a critical market for Fengbei Bio [12]. R&D and Competitive Position - R&D expenses as a percentage of revenue have decreased from 3.39% in 2023 to 2.75% in 2024, which is below the industry average [20][21]. - The company’s biodiesel production capacity is 105,000 tons, significantly lower than competitors like Zhuoyue New Energy and Jiaao Environmental Protection [22]. Future Outlook - The company is shifting its sales focus to emerging markets outside the EU, such as Switzerland and Singapore, in response to changing policies [15]. - The company’s financial health is concerning, with cash reserves of 167 million yuan against short-term borrowings of 173 million yuan, indicating potential liquidity issues [24][25].

雷递网 雷建平 8月8日 苏州丰倍生物科技股份有限公司（简称："丰倍生物"）日前IPO过会，准备在科创板上市。丰倍生物计划募资7.5亿。 | 序号 | 项目名称 | 投资总额 | 拟投入募集 | 项目备案 | 项目环评 | | --- | --- | --- | --- | --- | --- | | | | | 资金金额 | 批文 | 情况 | | | 新建年产30万吨油酸甲 酯、1万吨工业级混合 | 104.000.00 | 75,000.00 | 张保投资备 (2020) | 张保审批 (2024) | | | 油、5 万吨农用微生物菌 | | | | | | | 剂、1 万吨复合微生物肥 | | | 225 号 | 32号 | | | 料及副产品生物柴油 5 万 | | | | | | | 吨、甘油 0.82 万吨项目 | | | | | | | 合计 | 104,000.00 | 75.000.00 | | | 丰倍生物此轮融资用于新建年产30万吨油酸甲酯、1万吨工业级混合油、5万吨农用微生物菌剂、1万吨复合微生物肥料及副产品生物柴油5万吨、甘油0.82 万吨项目。 招股书显示，丰倍生物2022年、 ...

财务方面，于2022年度、2023年度及2024年度，丰倍生物实现营业收入约为17.09亿元、17.28亿元、 19.48亿元人民币；同期，公司实现净利润分别为约1.33亿元、1.30亿元、1.24亿元人民币。 8月7日，苏州丰倍生物科技股份有限公司(简称：丰倍生物)通过上交所上市委会议。此次IPO的保荐人为 国泰海通证券，拟募资10亿元。 招股书显示，丰倍生物是一家废弃资源综合利用领域的高新技术企业，主要以废弃油脂生产资源化产 品。基于长期的研发投入和产业实践，公司在废弃油脂资源综合利用的深度及广度上不断拓展，形成 了"废弃油脂—生物燃料(生物柴油)—生物基材料"的废弃资源再生产业链。此外，公司还依托自身油脂 综合利用核心技术和渠道优势为客户提供油脂化学品。 截至2024年末，公司现有生物柴油产能10.5万吨，产能规模位居我国生物柴油行业第六。结合主要资源 化产品生物柴油的产量来看，根据USDA统计，2024年我国生物柴油产量约为171万吨，发行人生物柴油 产量为8.01万吨，对应以产量计的公司生物柴油市场占有率约为4.68%。 生物基材料方面，公司已成功推广生物基材料在农化等细分领域的应用，其产品符合安全 ...

Group 1 - The core viewpoint of the article is that Suzhou Fengbei Biotechnology Co., Ltd. has successfully passed the IPO review on the Shanghai Stock Exchange, indicating a positive step towards its public listing [1] - Fengbei Biotechnology is a high-tech enterprise in the field of comprehensive utilization of waste resources, primarily producing resource-based products from waste oils [1] - The company aims to raise approximately 750 million yuan through its IPO, which will be invested in various projects including the production of 300,000 tons of oleic acid methyl ester and 10,000 tons of industrial-grade mixed oil [1] Group 2 - The listing committee has requested Fengbei Biotechnology to explain the reasons and rationality behind the expected decrease or stability in sales and management expenses for 2024, despite anticipated adjustments in customer and product structures and continued revenue growth [1] - The committee also requires the company to address the authenticity of sales revenue and expenses related to industrial-grade mixed oil, considering the main operational data and performance changes for 2024 [1] - Additionally, the committee has asked Fengbei Biotechnology to assess the risks of declining biofuel revenue, the sustainability of industrial-grade mixed oil revenue growth, and the stability of the company's operating performance in light of changes in product structure and competitive advantages [2]

丰倍生物沪主板IPO过会。 8月7日，上交所上市委举行2025年第29次审议会议，审议苏州丰倍生物科技股份有限公司（简称"丰倍 生物"）首次公开发行事项，最终公司顺利过会。 丰倍生物是一家废弃资源综合利用领域的高新技术企业，主要以废弃油脂生产资源化产品。基于长期的 研发投入和产业实践，公司在废弃油脂资源综合利用的深度及广度上不断拓展，形成了"废弃油脂—生 物燃料（生物柴油）—生物基材料"的废弃资源再生产业链。此外，公司还依托自身油脂综合利用核心 技术和渠道优势为客户提供油脂化学品。 作为国家级专精特新"小巨人"企业和苏州市独角兽培育企业，丰倍生物深知创新是企业发展的核心动 力。公司在研发领域持续投入大量资源，形成了以"基础研究、材料开发、应用开发"为核心的创新体 系。截至2025年3月31日，丰倍生物已拥有144项专利，其中包括31项国内发明专利和3项国际发明专 利。 业绩方面，2023年至2025年上半年，丰倍生物实现营收17.09亿元、19.48亿元和14.78亿元；净利润为1.3 亿元、1.24亿元和0.85亿元。 本次IPO，丰倍生物拟募资7.5亿元，分别投入到新建年产30万吨油酸甲酯、1万吨工业级混 ...

Group 1 - The global carbon reduction policies and environmental awareness are creating new development opportunities for the waste oil resource utilization industry [1] - Suzhou Fengbei Biological Technology Co., Ltd. (Fengbei Bio) is a representative enterprise in the domestic waste oil resource utilization field, accelerating its expansion in domestic and international markets [1] - Fengbei Bio plans to issue no more than 35.9 million shares on the Shanghai Stock Exchange, with the public offering accounting for no less than 25% of the total share capital after issuance, aiming to raise 750 million yuan for various production projects [1] Group 2 - Fengbei Bio is a high-tech enterprise in the waste resource utilization sector, primarily focusing on the resource utilization of waste oil, with a secondary emphasis on oil chemical products [2] - The company is expanding the application boundaries of waste oil resource products into various industrial fields, particularly gaining a competitive advantage in the agricultural sector [2] - The capacity expansion will achieve three strategic values: breaking existing production constraints, leveraging economies of scale to reduce marginal costs, and consolidating market leadership to strengthen competitive advantages [2]

Core Viewpoint - The company, Dadi Ocean, is making a third attempt to acquire Zhejiang Huguo Waste Management Co., Ltd. for 135 million yuan, significantly lower than previous offers, amid performance pressures and a substantial decline in net profit in Q1 2025 [1][6][8]. Group 1: Acquisition Details - Dadi Ocean plans to acquire 100% of Zhejiang Huguo's shares, which integrates technology with waste recycling [3][9]. - The acquisition price has dropped by 7.75 billion yuan compared to previous attempts, reflecting an 85.16% decrease [6][7]. - The funding for the acquisition will come from the company's own or self-raised funds, with no adverse impact on its financial status [6]. Group 2: Financial Performance - In Q1 2025, Dadi Ocean reported a net profit decline of over 90%, marking its worst quarterly performance since going public [1][8]. - The company's revenue for Q1 2025 was approximately 212.9 million yuan, a 32.29% increase year-on-year, but net profit was only 731,000 yuan [8]. - The acquisition of Zhejiang Huguo is expected to enhance Dadi Ocean's profitability and operational efficiency if successful [6][8]. Group 3: Market Context - The waste resource utilization industry is projected to have significant growth potential driven by policy support, market demand, and technological innovation [10]. - The acquisition will allow Dadi Ocean to expand its business into the residential waste recycling market, enhancing its industry positioning [9].